DBV Technologies SA - American (DBVT) AI Stock Analysis

• Market Cap: $537.18M
• Dividend Yield: N/A
• Average Volume (3M): 165.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.08
• Revenue Growth: N/A
• EPS Growth: 1.29%
• Country: US
• Employees: 106
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 35,965,584
• 10 Day Avg. Volume: 116,176
• 30 Day Avg. Volume: 165,002
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.17
• Price to Sales (P/S): 23.14
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 350.36
• Enterprise Value/Gross Profit: -20.86
• Enterprise Value/Ebitda: -2.09
• 1Y Price Target: $20.00
• Price Target Upside: 43.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -2.28
• Revenue Forecast (FY): $4.88M

• Rating: 48 Neutral
• Price Target: $14.00 ▲(0.21% Upside)

DBV Technologies SA's overall stock score is primarily impacted by its financial instability, characterized by declining revenues and persistent losses. While technical indicators show some positive trends, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Innovative Technology

The proprietary Viaskin technology offers a unique approach to allergy treatment, potentially providing a competitive advantage in the biotechnology sector.

Low Leverage

Low leverage indicates financial prudence, allowing for greater flexibility in funding operations and strategic initiatives without excessive debt burden.

Partnership Opportunities

Partnerships with pharmaceutical firms can provide crucial funding and accelerate product development, enhancing long-term growth prospects.

Negative Factors

Revenue Decline

Significant revenue contraction indicates challenges in product sales and market penetration, potentially impacting future growth and sustainability.

Negative Cash Flow

Negative cash flow highlights liquidity challenges, limiting the company's ability to invest in R&D and operational expansion without external financing.

Persistent Losses

Ongoing losses suggest inefficiencies and high operational costs, which could hinder profitability and require strategic restructuring to improve margins.

DBV Technologies SA - American Business Overview & Revenue Model

Company Description

DBV Technologies SA is a biopharmaceutical company focused on developing and commercializing innovative therapies for food allergies and immunological diseases. The company is primarily engaged in the research and development of its proprietary Viaskin technology, which aims to provide a safe and effective method for desensitizing patients to allergens through epicutaneous immunotherapy. DBV Technologies operates in the biotechnology sector, with a core emphasis on addressing unmet medical needs in allergy treatment.

How the Company Makes Money

DBV Technologies generates revenue primarily through the development and commercialization of its therapeutic products, particularly those that leverage its Viaskin technology for treating food allergies. The company may receive funding through partnerships with other pharmaceutical firms for co-development agreements, licensing deals, or joint ventures that provide upfront payments, milestone payments, and royalties on sales. Additionally, DBV Technologies may obtain revenue through government grants and research funding aimed at supporting the development of its innovative therapies. The company's earnings are significantly influenced by the successful progression of its clinical trials and the eventual commercialization of its products.

DBV Technologies SA - American Financial Statement Overview

Summary

DBV Technologies SA faces financial instability with declining revenues and persistent losses. Despite low leverage, negative returns and cash flow issues present significant challenges. The company needs to address its revenue contraction and improve operational efficiency to stabilize its financial position.

Income Statement

DBV Technologies SA has experienced a significant decline in revenue from $15.73 million in the previous year to $2.57 million in the TTM (Trailing-Twelve-Months), indicating a revenue contraction. The company also posted negative EBIT and net income margins, reflecting ongoing operational challenges and high expenses relative to revenue. Despite gross profit being positive, the net profit margin remains negative.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio, indicating limited leverage which is a positive aspect. However, the return on equity is negative due to the net losses, and the equity ratio has declined, indicating reduced financial stability. This suggests potential challenges in maintaining equity levels without external financing.

Cash Flow

DBV Technologies SA reported a negative free cash flow, with a deterioration in operating cash flow compared to the previous year. The free cash flow to net income ratio is negative, indicating cash flow issues. Despite a slight improvement in financing cash flow, the overall cash flow situation points to liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	511.00K	2.57M	15.73M	4.80M	5.71M	11.28M
Gross Profit	-8.58M	-4.26M	15.73M	-15.50M	-3.56M	11.28M
EBITDA	-85.80M	-111.18M	-85.98M	-76.68M	-91.16M	-124.83M
Net Income	-122.94M	-113.92M	-72.73M	-96.30M	-97.81M	-159.56M
Balance Sheet
Total Assets	110.50M	65.66M	182.99M	246.50M	146.72M	333.87M
Cash, Cash Equivalents and Short-Term Investments	69.84M	32.46M	141.37M	209.20M	77.30M	196.35M
Total Debt	0.00	7.80M	6.55M	4.15M	10.66M	15.47M
Total Liabilities	57.64M	38.27M	42.80M	52.00M	47.45M	81.87M
Stockholders Equity	52.85M	27.39M	140.19M	194.50M	99.27M	205.49M
Cash Flow
Free Cash Flow	-97.70M	-106.81M	-80.33M	-56.45M	-109.16M	-206.48M
Operating Cash Flow	-97.83M	-104.47M	-79.65M	-55.70M	-108.24M	-203.10M
Investing Cash Flow	139.00K	-757.00K	-808.00K	-100.00K	-433.00K	-3.51M
Financing Cash Flow	117.80M	587.00K	6.77M	194.10M	274.00K	149.55M

DBV Technologies SA - American Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DBVT, the sentiment is Positive. The current price of 13.97 is below the 20-day moving average (MA) of 15.29, above the 50-day MA of 12.46, and above the 200-day MA of 8.96, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 48.35 is Neutral, neither overbought nor oversold. The STOCH value of 15.71 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DBVT.

DBV Technologies SA - American Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	58 Neutral	$490.84M	―	-38.87%	―	―	―
PRTC	58 Neutral	$403.97M	9.39	14.55%	―	1268.81%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LRMR	49 Neutral	$275.60M	―	-78.24%	―	―	-67.41%
DBVT	48 Neutral	$537.18M	―	-234.58%	―	―	1.29%
KRRO	45 Neutral	$317.88M	-3.47	-58.34%	―	―	61.73%
LXEO	38 Underperform	$442.81M	―	-80.69%	―	―	4.97%

DBV Technologies SA - American Corporate Events

DBV Technologies Appoints Dr. Philina Lee to Board

On October 30, 2025, DBV Technologies announced the appointment of Dr. Philina Lee to its Board of Directors, filling the vacancy left by Daniel Soland. Dr. Lee, who brings extensive experience from her previous roles at Blueprint Medicines and Fusion Pharmaceuticals, will also serve on the Compensation Committee. Her appointment, subject to shareholder approval, is expected to enhance DBV’s strategic direction as the company advances its VIASKIN® Peanut program for children with peanut allergies.

The most recent analyst rating on (DBVT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

DBV Technologies Reports Q3 2025 Financial Results

DBV Technologies S.A. is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions, utilizing its proprietary VIASKIN® patch technology to address significant unmet medical needs.

DBV Technologies Announces Board Member Resignation

On September 18, 2025, DBV Technologies announced the resignation of Daniel Soland from its Board of Directors and compensation committee, effective immediately. Soland’s departure was amicable, and the company expressed gratitude for his contributions since 2015. The Board will continue with nine members and plans to appoint a new member to fill the vacancy, subject to shareholder approval at the next Annual General Meeting.

The most recent analyst rating on (DBVT) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.

DBV Technologies Launches $150M ATM Equity Offering

On September 5, 2025, DBV Technologies announced the establishment of an at-the-market (ATM) equity offering program on Nasdaq, allowing the company to sell up to $150 million in American Depositary Shares (ADS) through Citizens JMP Securities. The proceeds from this program are intended to support the Biologics License Application for the VIASKIN Peanut patch and other corporate purposes, with the sales being conducted at market prices and subject to regulatory limits.

The most recent analyst rating on (DBVT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.